What is Tremelimumab used to treat?

Tremelimumab is an immune checkpoint inhibitor targeting CTLA-4 and belongs to a new generation of tumor immunotherapy drugs. CTLA-4 is a negative immune regulatory molecule. When its activity is inhibited, T cells can recognize and attack tumor cells more effectively. By blocking the CTLA-4 signal, temsilimumab relieves the inhibition of T cells, allowing the body's immune system to gain stronger attack power in the face of tumors. This drug has unique advantages in tumor immunotherapy and is especially suitable for solid tumors that are difficult to control with traditional treatments, including unresectable hepatocellular carcinoma (uHCC) and certain types of metastatic non-small cell lung cancer (mNSCLC).

In the treatment of hepatocellular carcinoma, temsitumumab is often used in combination with durvalumab (Durvalumab). The combination of the two can enhance T cell activity through dual immune pathways and stimulate the body's anti-tumor immune response. Compared with single drug therapy, the combination regimen can activate the immune system more comprehensively, improve the therapeutic effect, and show controllable safety in clinical practice. In the treatment of non-small cell lung cancer, temsitumumab can be used in combination with durvalumab and platinum chemotherapy drugs, and is suitable for metastatic patients without EGFR mutations or ALK gene abnormalities. Through multi-drug combination, the potential of immunotherapy can be fully utilized, and chemotherapy drugs can be used to directly inhibit the growth of tumor cells, achieving a synergistic effect between immunotherapy and traditional treatment.

The clinical significance of temsitumumab lies not only in its direct anti-tumor effect, but also in that it provides a scientific basis for combined immunotherapy. By blocking CTLA-4, T cells gain stronger anti-tumor capabilities and at the same time form immune memory in the body, which may provide certain protection against tumor recurrence. This mechanism explains why temsitumumab exhibits durable immune responses in the treatment of liver and lung cancer. International multi-center clinical trials and studies have shown that temsitumumab combined with immunotherapy has the potential to improve patient survival expectations and delay disease progression, and has become an important reference for modern cancer treatment.

Reference: https://www.drugs.com/mtm/tremelimumab.html